Novel obesity drugs, oncology biosimilars to impact markets

October 2009
PharmacoEconomics & Outcomes News;10/3/2009, Issue 588, p11
The article discusses the statement by Decision Resources that by 2018, obesity drug market is expected to grow more than six times and biosimilars are expected to erode sales of three branded oncology drugs. According to this report, biosimilars of the oncology drugs rituximab, cetuximab and trastuzumab are expected to erode 8.2 billion U.S. dollars in sales in Europe and in the U.S. Medications that are expected to capture 87% of total obesity market in 2018 include lorcaserin and pramlintide/leptin combination therapies.


Related Articles

  • Burkitt Lymphoma in Elderly Patients. Petković, Ivan; Mihailović, Dragan; Krstić, Miljan; Pejčić, Ivica; Vrbić, Svetislav; Balić, Mirjana // Acta Facultatis Medicae Naissensis;2013, Vol. 30 Issue 2, p103 

    Burkitt lymphoma (BL) is a disease of predominantly young population, while in the elderly it occurs as a rare neoplasm. Elderly patients (age >60 years) represent a significant problem because of the inability to apply effective aggressive chemotherapy in these cases. The risk of induction...

  • The Global Epidemic of Obesity: Why Global Approaches Won't Work. Miller, Wayne C. // Healthy Weight Journal;Nov/Dec2001, Vol. 15 Issue 6, p81 

    Editorial. Explores the global epidemic of obesity. Efforts to prevent overweight and obesity; Assumptions underlying obesity treatment paradigms; Efficiency of obesity treatment programs.

  • Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphoma. Hess, Georg; Flohr, Thomas; Kolbe, Karin; Bonn, Sarah; Schuler, Martin; Derigs, Hans Günter; Huber, Christoph // Annals of Hematology;Nov2006, Vol. 85 Issue 11, p769 

    To better define the role of rituximab in salvage and high-dose therapy (HDT) for relapsed or refractory non-Hodgkin’s lymphoma (NHL), patients treated before the implementation of rituximab in salvage and HDT ( n=57, control group) were compared with patients with rituximab included in...

  • Gemcitabine/rituximab.  // Reactions Weekly;May2015, Vol. 1550 Issue 1, p106 

    The article presents a case study of a 61-year-old woman who developed coronary artery vasospasm (CAV) following therapy with drugs gemcitabine and rituximab and mentions that the woman had been diagnosed with chronic lymphocytic leukaemia and had already received five cycles of chemotherapy.

  • Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen. Solimando, Dominic A.; Waddell, J. Aubrey // Hospital Pharmacy;Dec2016, Vol. 51 Issue 11, p888 

    The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and...

  • Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised Phase 3 trial. Mead, Adam // Current Medical Literature: Leukemia & Lymphoma;2014, Vol. 22 Issue 2, p51 

    The article discusses a study published in the periodical "Lancet Oncology" which compared the efficacy of rituximab treatment with watchful waiting (WW) strategy in patients with asymptomatic, advanced-stage, low tumor follicular lymphoma (FL). Topics discussed include research assumptions that...

  • Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma. Pellicelli, Adriano M.; D'Ambrosio, Cecilia; Dessanti, Maria L.; Villani, Roberto; Fondacaro, Lucia; Miglioresi, Lucia; Grillo, Lucia R.; Andreoli, Arnaldo // Annals of Hepatology: Official Journal of the Mexican Associatio;Sep/Oct2015, Vol. 14 Issue 5, p756 

    Rituximab is a chimeric anti-CD20 monoclonal antibody that is a widely used for the treatment of B cells non-Hodgkin lymphoma. The use of chemotherapy regimens containing rituximab in HCV-positive patients with non-Hodgkin lymphoma has been associated with liver dysfunction, but no cases of...

  • Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. Zengjun Li; Fei Li; Shuhua Yi; Zhimin Gu; Zhen Yu; Yan Xu; Xiaoyan Feng; Wei Liu; Dehui Zou; Junyuan Qi; Fenghuang Zhan; Lugui Qiu // BMC Cancer;Jul2015, Vol. 15 Issue 1, p1 

    Background: Rituximab has been confirmed to improve the survival of patients with B cell indolent non-Hodgkin lymphomas (B-iNHLs) in Western world as previously reported, however, it is rarely reported in Chinese cohort. This study is to investigate the efficacy and safety of rituximab-based...

  • Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Xu, Zi-Zhen; Xia, Zu-Guang; Wang, Ai-Hua; Wang, Wen-Fang; Liu, Zhi-Yin; Chen, Li-Yun; Li, Jun-Min // Annals of Hematology;Oct2013, Vol. 92 Issue 10, p1351 

    Diffuse large B cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma and accounts for approximately 30 % of newly diagnosed lymphoid neoplasms in Western countries, and 40-50 % in China. A better understanding of the biology of DLBCL is needed for the development of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics